Knocking down the expression of wild-type Ras proteins [8, 19], or reducing their activation by eNOS [8] or SOS [9], inhibits cell viability, transformation, and/or tumorigenic growth of KRAS mutation-positive human cancer cell lines. The gene discussed is KRAS; the disease is cancer.